StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
2662
This month
67
This week
15
This year
349
Today
7
Yesterday
12
Publishing Date
2024 - 04 - 17
7
2024 - 04 - 16
5
2024 - 04 - 15
3
Sector
Commercial services
2
Health technology
6
Manufacturing
3
Professional, scientific, and technical services
2
Technology services
1
Tags
Acquisition
13
Agreement
18
Awards
10
Biopharma
14
Business
21
Cancer
10
Care
10
Ceo
11
Change
9
Collaboration
10
Commercial
15
Company
17
Conference
97
Corporation
31
Deadline
12
Earnings
10
Energy
21
Expansion
11
Fda
9
Financial
115
First
213
For
204
Global
25
Group
33
Growth
30
Health
15
International
17
Key
33
Management
11
Market
88
Medical
17
Meeting
38
Million
39
N/a
1017
Nasdaq
11
Offering
27
One
26
Pharm-country
10
Pharmaceuticals
26
Platform
12
Presentation
13
Program
18
Reach
20
Report
76
Research
27
Results
174
Revenue
11
Sales
15
Service
9
Services
17
Set
27
Solution
9
Solutions
15
Study
15
Technology
23
Therapeutics
43
Treatment
19
Trial
26
Update
23
Year
50
Entities
Atai life sciences n.v.
1
Biorestorative therapies, inc.
1
Celldex therapeutics, inc.
1
Compass therapeutics inc
1
Evolus, inc.
1
Gritstone oncology, inc.
1
Hyperfine inc - class a
1
Intra-cellular therapies inc.
1
Myriad genetics, inc.
1
Neumora therapeutics, inc.
1
Palisade bio inc
1
Relx plc
2
Sage therapeutics, inc.
1
The descartes systems group inc.
1
Symbols
ATAI
1
BRTX
1
CLDX
1
CMPX
1
DSGX
1
EOLS
1
GRTS
1
HYPR
1
ITCI
1
MYGN
1
NMRA
1
PALI
1
RELX
2
SAGE
1
Exchanges
Nasdaq
13
Nyse
2
Crawled Date
2024 - 04 - 17
7
2024 - 04 - 16
5
2024 - 04 - 15
3
Crawled Time
05:00
1
07:00
1
11:00
5
12:00
5
13:00
1
16:00
1
22:00
1
Source
www.biospace.com
3
www.globenewswire.com
10
www.prnewswire.com
2
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
published :
This week
tags :
Study
save search
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
Published:
2024-04-17
(Crawled : 22:00)
- biospace.com/
EOLS
|
News
|
$11.64
-3.4%
-3.52%
270K
|
Health Technology
|
-1.49%
|
O:
-1.49%
H:
0.0%
C:
0.0%
jeuveau
publication
for
study
Leading Institutions Enroll First Alzheimer’s Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study
Published:
2024-04-17
(Crawled : 16:00)
- biospace.com/
HYPR
|
News
|
$0.9129
-7.79%
-8.45%
80K
|
Manufacturing
|
-8.08%
|
O:
0.0%
H:
0.0%
C:
-8.08%
first
alzheimer’s
care
enroll
therapy
study
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Published:
2024-04-17
(Crawled : 12:00)
- globenewswire.com
CLDX
|
News
|
$39.66
2.75%
2.67%
910K
|
Health Technology
|
0.23%
|
O:
0.23%
H:
0.0%
C:
0.0%
urticaria
study
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published:
2024-04-17
(Crawled : 12:00)
- biospace.com/
SAGE
|
News
|
$12.585
-19.48%
-24.2%
4.3M
|
Health Technology
|
-17.57%
|
O:
-15.02%
H:
3.55%
C:
-3.01%
sage-718
disease
treatment
topline
parkinson’s
therapeutics
results
study
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
Published:
2024-04-17
(Crawled : 11:00)
- globenewswire.com
ATAI
|
News
|
$1.98
-7.91%
-8.59%
1.5M
|
Manufacturing
|
4.87%
|
O:
4.87%
H:
0.0%
C:
0.0%
bpl-003
life
publication
sciences
study
Every Rand Lost to Fraud in South Africa Costs Firms R3.64 According to LexisNexis True Cost of Fraud Study
Published:
2024-04-17
(Crawled : 07:00)
- prnewswire.com
RELX
|
News
|
$41.45
0.41%
0.0%
750K
|
Commercial Services
|
0.05%
|
O:
1.11%
H:
0.0%
C:
-1.05%
lexisnexis
africa
study
Every Dirham Lost to Fraud in UAE Costs Firms AED$4.19 According to LexisNexis True Cost of Fraud Study
Published:
2024-04-17
(Crawled : 05:00)
- prnewswire.com
RELX
|
News
|
$41.45
0.41%
0.0%
750K
|
Commercial Services
|
0.05%
|
O:
1.11%
H:
0.0%
C:
-1.05%
lexisnexis
study
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
Published:
2024-04-16
(Crawled : 13:00)
- globenewswire.com
MYGN
|
News
F
|
$18.66
-1.37%
-1.39%
550K
|
Health Technology
|
-2.76%
|
O:
-2.61%
H:
0.0%
C:
0.0%
prequel
positive
for
study
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
Published:
2024-04-16
(Crawled : 12:00)
- globenewswire.com
PALI
|
$6.54
10.29%
9.33%
1.6M
|
Manufacturing
|
60.78%
|
O:
113.15%
H:
10.29%
C:
-32.23%
pali-2108
study
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Published:
2024-04-16
(Crawled : 12:00)
- globenewswire.com
CMPX
|
$1.52
-3.19%
-3.29%
120K
|
Professional, Scientific, and T...
|
2.28%
|
O:
2.93%
H:
3.8%
C:
-0.63%
ctx-8371
first
tumors
therapeutics
study
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
Published:
2024-04-16
(Crawled : 12:00)
- globenewswire.com
BRTX
|
$1.37
4.58%
4.38%
660K
|
Professional, Scientific, and T...
|
0.77%
|
O:
9.23%
H:
15.49%
C:
-7.75%
brtx-100
fda
clearance
study
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Published:
2024-04-16
(Crawled : 11:00)
- globenewswire.com
ITCI
1 d
|
$76.68
-3.96%
-4.12%
2.9M
|
Health Technology
|
18.82%
|
O:
14.75%
H:
12.75%
C:
6.04%
positive
topline
therapy
results
study
Descartes’ Study Reveals 54% of Supply Chain and Logistics Operations are Prioritizing Automation to Mitigate Workforce Shortages
Published:
2024-04-15
(Crawled : 11:00)
- globenewswire.com
DSGX
|
$90.51
-0.43%
-0.43%
260K
|
Technology Services
|
-1.18%
|
O:
-1.18%
H:
0.0%
C:
0.0%
study
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
Published:
2024-04-15
(Crawled : 11:00)
- globenewswire.com
NMRA
|
$10.575
-3.51%
-3.64%
610K
|
|
-24.57%
|
O:
-20.17%
H:
11.46%
C:
0.99%
nmra-266
therapeutics
study
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
Published:
2024-04-15
(Crawled : 11:00)
- globenewswire.com
GRTS
|
$0.7448
-3.51%
-3.64%
3.1M
|
Health Technology
|
-18.03%
|
O:
-6.28%
H:
1.25%
C:
-13.83%
vaccine
results
study
platform
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.